CDMO Earnings

CDMO reported its FY2025Q2 earnings on 2024-12-10, showcasing a revenue of 33.48M against an estimate of 34.70M, resulting in a -3.51% surprise. The EPS was -0.27, surpassing the expected -0.13 by -107.69% . The stock experienced a 0.33% price change on the earnings day and a 0.73% change over the next five days, reflecting market reactions to the results.

Following CDMO's FY2025Q2 earnings announcement on 2024-12-10, the stock price moved by 0.33% on the day of the release. Over the subsequent five days, it saw a 0.73% change. Historically, CDMO's stock price tends to shift by an average of +7.07% in the 10 days leading up to earnings and +11.76% in the 10 days following, providing insight into potential market.

For 2025/Q3, analysts estimate CDMO’s annual revenue to reach 41.38M, while the EPS is projected at -0.04. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates No Change by 0% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between CDMO's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved No Change by 0% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, CDMO's stock price typically moves by +7.07% in the 10 days before its earnings and +11.76% in the 10 days after. For the upcoming 2025/Q3 earnings, analysts expect an EPS of -0.04 and revenue of 41.38M.

The earnings call reveals a mixed outlook. Financial performance shows modest revenue growth and improved gross margin, but rising SG&A expenses and a widened net loss raise concerns. The Q&A section highlights uncertainties in backlog burn rate and large pharma strategy. While new project agreements and capacity expansion are positive, financial instability and competition pose risks. The lack of a share repurchase program and unclear management responses further contribute to a neutral sentiment. Despite optimistic guidance and infrastructure investments, the absence of strong catalysts limits positive sentiment.